Incyte & Novartis enter phase II trials with Jakafi drug
Share this article
Partners are taking Jakafi drug into a second late-stage trial for COVID-19 patients on ventilators
On 5 May 2020, Incyte and Novartis announced that phase II clinical trials were entering a second and last stage for the Jakafi drug, also known as ruxolitinib. The drug will further be tested during phase III clinical trial on COVID-19 patients with acute respiratory distress syndrome (ARDS). Phase III will enable to evaluate Jakafi’s ability to treat cytokin storm, an immune overreaction which can cause severe complications.
Incyte guarantees that it’s manufacturing processes are running as usual with a special focus on the production of the Jakafi drug, securing a suitable volume to complete the clinical phases and enter the commercialisation phase, once validated.